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Glyceryl trinitrate is administered as a provocative test for migraine pain. Glyceryl trinitrate causes prolonged mechanical allodynia
in rodents, which temporally correlates with delayed glyceryl trinitrate-evoked migraine attacks in patients. However, the underlying
mechanism of the allodynia evoked by glyceryl trinitrate is unknown. The proalgesic transient receptor potential ankyrin 1 (TRPA1)
channel, expressed by trigeminal nociceptors, is sensitive to oxidative stress and is targeted by nitric oxide or its by-products. Herein,
we explored the role of TRPA1 in glyceryl trinitrate-evoked allodynia. Systemic administration of glyceryl trinitrate elicited in the
mouse periorbital area an early and transient vasodilatation and a delayed and prolonged mechanical allodynia. The systemic,
intrathecal or local administration of selective enzyme inhibitors revealed that nitric oxide, liberated from the parent drug by
aldehyde dehydrogenase 2 (ALDH2), initiates but does not maintain allodynia. The central and the final phases of allodynia
were respectively associated with generation of reactive oxygen and carbonyl species within the trigeminal ganglion. Allodynia
was absent in TRPA1-deficient mice and was reversed by TRPA1 antagonists. Knockdown of neuronal TRPA1 by intrathecally
administered antisense oligonucleotide and selective deletion of TRPA1 from sensory neurons in Advillin-Cre; Trpa1fl/fl mice
revealed that nitric oxide-dependent oxidative and carbonylic stress generation is due to TRPA1 stimulation, and resultant
NADPH oxidase 1 (NOX1) and NOX2 activation in the soma of trigeminal ganglion neurons. Early periorbital vasodilatation
evoked by glyceryl trinitrate was attenuated by ALDH2 inhibition but was unaffected by TRPA1 blockade. Antagonists of the
calcitonin gene-related peptide receptor did not affect the vasodilatation but partially inhibited allodynia. Thus, although both
periorbital allodynia and vasodilatation evoked by glyceryl trinitrate are initiated by nitric oxide, they are temporally and mech-
anistically distinct. While vasodilatation is due to a direct nitric oxide action in the vascular smooth muscle, allodynia is a neuronal
phenomenon mediated by TRPA1 activation and ensuing oxidative stress. The autocrine pathway, sustained by TRPA1 and NOX1/
2 within neuronal cell bodies of trigeminal ganglia, may sensitize meningeal nociceptors and second order trigeminal neurons to elicit
periorbital allodynia, and could be of relevance for migraine-like headaches evoked by glyceryl trinitrate in humans.
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Introduction
Occupational exposure to, or treatment with, organic ni-
trates has long been known to provoke headaches (Trainor
and Jones, 1966; Thadani and Rodgers, 2006). These obser-
vations have led to the clinical use of glyceryl trinitrate
(GTN) as a reliable provocation test for migraine attacks
(Sicuteri et al., 1987; Iversen et al., 1989; Thomsen et al.,
1994; Olesen, 2008). In most subjects, including healthy
controls, GTN administration causes a mild headache that
develops rapidly and is short-lived. However, after a remark-
able time lag (hours) from GTN exposure, migraineurs de-
velop severe headaches that fulfil the criteria of a typical
migraine attack (Sicuteri et al., 1987; Iversen et al., 1989;
Thomsen et al., 1994; Olesen, 2008). This ability of GTN to
provoke migraine is temporally dissociated from the imme-
diate and short-lived (510min) release of nitric oxide (NO)
(Persson et al., 1994) and the consequent cGMP-dependent
vascular responses (Guo et al., 2008). Thus, while vasodila-
tation by GTN/NO might account for the early dull head-
ache experienced by most subjects (Iversen and Olesen,
1996), it cannot explain the delayed headache symptoms
observed in migraineurs (Olesen, 2008).
Several mechanisms have been proposed to explain GTN-
evoked headaches, including degranulation of meningeal mast
cells (Reuter et al., 2001; Ferrari et al., 2016), phosphorylation
of extracellular signal-regulated kinase (ERK) in meningeal
arteries (Zhang et al., 2013), delayed meningeal inflammation
sustained by induction of NO synthase and prolonged NO
generation, and the release of calcitonin gene-related peptide
(CGRP) (Strecker et al., 2002; Ramachandran et al., 2014), a
primary migraine neuropeptide (Ho et al., 2010; Edvinsson,
2015). GTN administration to rodents and humans produces
a delayed and prolonged (hours) hyperalgesia that temporally
correlates with GTN-induced migraine-like attacks in humans
(Thomsen et al., 1996; Tassorelli et al., 2003; Bates et al.,
2010; Ferrari et al., 2016). However, the molecular processes
responsible for this delayed hyperalgesia in rodents and
humans are unknown.
Transient receptor potential (TRP) ion channels ex-
pressed by nociceptors play a major role in pain (Nilius
and Szallasi, 2014). NO can target the TRP ankyrin 1
(TRPA1) channel (Miyamoto et al., 2009), which is abun-
dantly expressed by a specific nociceptor subpopulation
(Nassini et al., 2014). TRPA1-positive sensory neurons ex-
press additional pain-inducing TRPs, including the vanilloid
1 (TRPV1) and vanilloid 4 (TRPV4) channels, as well as
the neuropeptides CGRP, substance P (SP), and neurokinin
A (NKA), which mediate neurogenic inflammation (Nassini
et al., 2014).
TRPA1 is uniquely sensitive to an unprecedented series of
oxidants and electrophiles, including reactive oxygen, nitro-
gen and carbonylic species, thereby sensing oxidative/nitra-
tive/carbonylic stress (Trevisani et al., 2007; Andersson
et al., 2008; Materazzi et al., 2008; Taylor-Clark et al.,
2009). TRPA1 is considered a major pain transducer since
TRPA1 inhibition attenuates different types of neuropathic
(Trevisan et al., 2016) and inflammatory (McNamara et al.,
2007; Trevisan et al., 2014) pain. TRPA1 may also contrib-
ute to migraine, since triggers of headache attacks can target
the channel in peptidergic nociceptors (Kunkler et al., 2011;
Shatillo et al., 2013; Denner et al., 2017; Borkum, 2018).
Furthermore, drugs (Andersson et al., 2011; Nassini et al.,
2015) or herbal preparations (Benemei et al., 2017) used for
migraine treatment inhibit or desensitize TRPA1.
As previously reported in rats (Di et al., 2016;
Kopruszinski et al., 2017) and mice (Farkas et al., 2016)
with systemic administration of NO donors, herein we
show that GTN produces an early (0–10min) and transient
vasodilation and a delayed and prolonged (0.5–8 h) mech-
anical allodynia in the cutaneous periorbital area in mice.
We found that allodynia, but not vasodilation, is prevented
by genetic deletion or pharmacological blockade of TRPA1.
NO, generated from GTN by aldehyde dehydrogenase 2
(ALDH2), is required to initiate the entire process, but is
not sufficient for its maintenance. TRPA1- and NADPH
oxidase (NOX)-dependent reactive oxygen species gener-
ation from cell bodies of trigeminal ganglion neurons main-
tains the first phase of sustained allodynia. Reactive oxygen
species-dependent peroxidation of membrane phospholipids
generates reactive carbonylic species, including 4-hydroxy-
nonenal (4-HNE), which activates TRPA1 to promote the
continuation and final phase of allodynia. CGRP released
from cutaneous nerve fibres contributes to the allodynia.
The autocrine function of nociceptor TRPA1 that, by gen-
erating oxidative stress, sustains GTN-induced allodynia,
highlights the unforeseen role of the channel in producing,
and possibly sensing, oxidative stress in cell bodies of pri-
mary sensory neurons, thereby contributing to periorbital
allodynia.
Materials and methods
Animals
In vivo experiments were in accordance with the European
Union Directive 2010/63/EU guidelines, the Italian legislation
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(DLgs 26/2014), and the University of Florence research
permit #194/2015-PR. The following mouse strains were
used: C57BL/6 (male, 20–25 g, 5–6weeks; Envigo); littermate
wild-type (Trpa1+ / + ) and TRPA1-deficient (Trpa/)
mice (25–30 g, 5–8weeks) (Kwan et al., 2006); wild-type
(Trpv4+ / + ) and TRPV4-deficient (Trpv4/) mice (25–30 g,
5–8weeks) (Liedtke and Friedman, 2003); and TRPV1-defi-
cient mice (Trpv1/; B6.129X1-Trpv1tm1Jul/J) backcrossed
with C57BL/6 mice (Trpv1+ / + ) for at least 10 generations
(Jackson Laboratories, 25–30 g, 5–8weeks). To selectively
delete the Trpa1 gene in primary sensory neurons, 129S-
Trpa1tm2Kykw/J mice (floxed TRPA1, Trpa1fl/fl, Stock No:
008649; Jackson Laboratories), which possess loxP sites on
either side of the S5/S6 transmembrane domains of the
Trpa1 gene, were crossed with hemizygous Advillin-Cre male
mice (Zurborg et al., 2011; Guan et al., 2016). The progeny
was genotyped by standard PCR for Trpa1 (PCR Protocol
008650, Jackson Laboratories; www.jax.org) and Advillin-
Cre (Guan et al., 2016). Mice negative for Advillin-Cre
(Adv-Cre; Trpa1fl/fl) were used as control. Successful
Advillin-Cre driven deletion of TRPA1 mRNA was confirmed
by RT-qPCR (Zappia et al., 2017). Mice were housed in a
temperature- and humidity-controlled vivarium (12-h dark/
light cycle, free access to food and water, 10 animals per
cage). Mice were acclimatized in a quiet, temperature-con-
trolled room (20–22C) for 1 h before behavioural studies be-
tween 9 am and 5pm. A randomization procedure (http://
www.randomizer.org/) was used to allocate animals to treat-
ments. Investigators were blinded to genotype and drug treat-
ments. For logistical reasons up to 18 mice could be studied on
any one day. In all cases, control and experimental groups
were studied on the same day, and experiments were replicated
on different days to generate results from the required number
of mice. Animals were anaesthetized with intraperitoneal (i.p.)
ketamine (90mg/kg) and xylazine (3mg/kg) and euthanized
with inhaled CO2 plus 10–50% O2.
Based on our experience in similar experimental settings and
on data published by others, we anticipated a standardized
difference of 1.8 standard deviations (SDs) between wild-type
and Trpa1/animals 1 h after exposure to GTN and control
treatments. Using G*Power (v3.1) (Faul et al., 2009), we deter-
mined that six animals per group were the minimum necessary
to detect the size effect in a post hoc t-test with type 1 and 2
error rates of 5 and 20%, respectively. Initial data acquisition
then showed that the effect size in some comparisons remained
meaningful but smaller than anticipated, 1.6 SDs. Sample
sizes of subsequent experiments were increased in order to
maintain power at 80%.
Reagents
Glyceryl trinitrate (GTN 50mg/50ml, Bioindustria L.I.M.
S.p.A.) or its vehicle (5% glucose and 1.5% propylene
glycol in sterile water) were used. HC-030031 [2-(1,3-dime-
thyl-2, 6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-iso-
propylphenyl) acetamide] was synthesized as previously
described (Materazzi et al., 2008). If not otherwise indicated,
reagents were obtained from Sigma-Aldrich. The vehicle,
except for GTN or where expressly indicated, was 4% dime-
thyl sulfoxide (DMSO) plus 4% Tween 80 in isotonic saline,
NaCl 0.9%.
Behavioural tests
Mechanical allodynia
Mechanical allodynia was evaluated by applying von Frey fila-
ments to the periorbital region over the rostral portion of the
eye (periorbital mechanical allodynia, PMA) (Elliott et al.,
2012) or to the posterior hind paw of mice, before (basal
threshold) and 24 h after GTN (1, 5 and 10mg/kg) or vehicle.
Some C57BL/6, Trpa1+ / + and Trpa1/ mice were injected
[10 ml/site, subcutaneously (s.c.)] with allyl isothiocyanate
(AITC, 10 nmol in 2.5% DMSO in 0.9% NaCl), GTN
(10 mg/site), S-nitroso-N-acetylpenicillamine (SNAP, 40 mg/site
in 2.5% DMSO in 0.9% NaCl), CGRP (0.5–5 mg/site in
0.9% NaCl) or their vehicles, and PMA was assessed before
and 6h after treatment. Additional C57BL/6 mice received
resiniferatoxin (50 mg/kg, s.c.) or its vehicle (10% ethanol
and 10% Tween 80 in 0.9% NaCl) (Pecze et al., 2009).
Seven days after resiniferatoxin, when responses (the eye
wiping test, see below) to capsaicin were abolished, GTN
(10mg/kg, i.p.)-evoked PMA and H2O2 levels were evaluated.
TRPA1 antisense (50-TATCGCTCCACATTGCTAC-30) or
mismatch control (50-ATTCGCCTCACATTGTCAC-30) oligo-
nucleotide (TRPA1 antisense or mismatch oligonucleotide)
were administered to C57BL/6 mice by intrathecal injection
(5 nmol/5 ml) (Bonet et al., 2013) for four consecutive days.
On Day 5, the efficiency of TRPA1 silencing was tested by
eye wiping responses to AITC and the Trpa1 mRNA content
in trigeminal ganglion neurons, and PMA evoked by GTN
(10mg/kg, i.p.) and H2O2 levels were evaluated. Adv-Cre
+ ;
Trpa1fl/fl and Adv-Cre; Trpa1fl/fl received GTN (10mg/kg,
i.p.) or its vehicle and PMA and H2O2 levels in trigeminal
ganglion neurons (collected 2 h after GTN/vehicle) were
evaluated.
The mechanical threshold was calculated by the up-and-
down paradigm (Dixon, 1980). All the drugs, at the maximum
used doses, did not evoke any direct nociceptive/allodynic re-
sponses or locomotor impairment. Doses and routes of admin-
istration of drugs and their targets are reported in
Supplementary Table 1. Times of administration are reported
in boxes placed above graphs.
Eye wiping test
The number of eye wiping movements, following the instilla-
tion of eye drops of capsaicin (1 nmol/5 ml), AITC (10 nmol/
5 ml) or vehicle (2% and 4% DMSO, respectively) to the con-
junctiva, was recorded for a 10-min time period (Nassini et al.,
2012).
Cell culture and isolation of primary
sensory neurons
HEK293 cells (American Type Culture Collection; ATCC

CRL-1573
TM
), cultured according to the manufacturer’s in-
structions, were transiently transfected with the cDNAs (1 mg)
codifying for wild-type (hTRPA1-HEK293) or mutant 3C/K-Q
human TRPA1 (C619S, C639S, C663S, K708Q; 3C/K-Q
hTRPA1-HEK293) (Hinman et al., 2006) using the
jetPRIME

transfection reagent (Polyplus-transfection

SA) ac-
cording to the manufacturer’s protocol. Primary trigeminal
ganglion neurons were isolated from C57BL/6 or Trpa1+ / +
and Trpa1/ mice, and cultured as previously described
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(Nassini et al., 2012). To obtain trigeminal neuronal and sat-
ellite glial cell (SGC) mixed cultures or SGC-enriched cultures,
the protocol reported previously was used (Chung et al.,
2015).
Calcium imaging assay
Intracellular calcium mobilization, [Ca2+ ]i, was measured in
transfected HEK293 cells and in trigeminal ganglion neurons,
as reported previously (Nassini et al., 2012). Trigeminal gan-
glion neurons were challenged with GTN (10–300 mM), SNAP
(30 mM), AITC (10 mM) or their respective vehicle. Capsaicin
(0.1 mM) was used to identify capsaicin-sensitive neurons.
Some experiments were performed in the presence of HC-
030031 (50 mM), capsazepine (10 mM), HC-067047 (30 mM),
carboxy-PTIO (cPTIO, 100mM) and disulfiram (1 mM). Buffer
solution containing 0.5% DMSO was used as vehicle for
SNAP and all inhibitors/scavenger. Wild-type or mutant
hTRPA1-HEK293 cells were challenged with GTN (100 mM),
menthol (100 mM) or their vehicle.
H2O2 assay
H2O2 was determined by using the Amplex Red

assay
(Invitrogen), in C57BL/6 mice, in trigeminal ganglion neurons
before or after (0.5–6 h) GTN (10mg/kg, i.p.), and 2h after
GTN/vehicle in mice pretreated (0.5 h before GTN) with
cPTIO (0.6mg/kg, i.p.) and disulfiram (100mg/kg, i.p.) or
treated (1 h after GTN) with HC-030031 (100mg/kg, i.p.)
and alpha lipoic acid (100mg/kg i.p.), or desensitized with
resiniferatoxin or silenced with TRPA1 antisense or mismatch
oligonucleotide; in dorsal horn of brain stem before and after
(1 and 2 h, respectively) GTN. In Trpa1+ / + and Trpa1/, and
in Adv-Cre; Trpa1fl/fl and Adv-Cre; Trpa1fl/fl mice H2O2 was
2 h after GTN.
Increase in H2O2 release was quantified in trigeminal
neuron-SGCs mixed and SGC-enriched primary culture after
challenge with GTN (10, 50 and 100mM), AITC (30 mM),
SNAP (100 mM) or their vehicle (0.3% DMSO for AITC and
SNAP) in the presence of HC-030031 (50 mM) or its vehicle
(0.5% DMSO in Krebs-Ringer phosphate buffer), or in a
Ca2+ -free Krebs-Ringer phosphate (KRP) buffer containing
EDTA (1mM) or after a pre-exposure to a high concentration
of capsaicin (10 mM, 20min) (Holzer, 1991). The detailed
method is reported in the Supplementary material.
Immunofluorescence
Anaesthetized C57BL/6 and Trpa1+ / + and Trpa1/ mice
treated with GTN (10mg/kg, i.p.) or its vehicle were transcar-
dially perfused with PBS, followed by 4% paraformaldehyde.
Trigeminal ganglion neurons and brainstem were removed,
postfixed for 24 h, and paraffin embedded or cryoprotected
(4C, overnight) in 30% sucrose. Cryosections (10 mm) of
brainstem and formalin fixed paraffin-embedded sections
(5 mm) of trigeminal ganglion neurons were incubated with
the following primary antibodies: 4-HNE (ab48506, 1:40,
HNEJ-2, Abcam), TRPA1 (ab58844, 1:400, Abcam), NOX1
(SAB2501686, 1:250), NOX2 (ab80897, 1:200, Abcam),
NOX4 (ab109225, 1:200, Abcam), glutamine synthetase
(G2781, 1:400) (1 h, room temperature) diluted in phos-
phate-buffered saline (PBS) and 2.5% normal goat serum
(NGS). Sections were then incubated with fluorescent second-
ary antibodies: polyclonal Alexa Fluor

488, and polyclonal
Alexa Fluor

594 (1:600, Invitrogen) (2 h, room temperature)
and coverslipped. The analysis of negative controls (non-
immune serum) was simultaneously performed to exclude the
presence of non-specific immunofluorescent staining, cross-
immunostaining, or fluorescence bleed-through. Tissues were
visualized, and digital images were captured using an
Olympus BX51 (Olympus srl). 4-HNE staining in trigeminal
ganglion was evaluated as the fluorescence intensity measured
by an image processing software (ImageJ 1.32 J, National
Institutes of Health). Data are expressed as mean fluorescence
intensity (% of basal).
4-HNE staining was determined in trigeminal ganglion neu-
rons collected from C57BL/6 mice before (basal level) or after
(0.5, 1, 2, 3, 4, 6 h) GTN (10mg/kg, i.p.) and 4h after GTN/
vehicle administration in C57BL/6 mice pretreated with cPTIO
(0.6mg/kg, i.p. given 0.5 h before GTN) or N-acetyl-L-cysteine
(NAC, 250mg/kg, i.p., given 0.5 h before GTN) or treated
with HC-030031 or alpha lipoic acid (both 100mg/kg i.p.,
given 3 h after GTN) and in Trpa1+ / + and Trpa1/ mice,
and in dorsal horn of brain stem collected from C57BL/6
mice before and after (1 and 2h) GTN.
Mouse trigeminal neuron-SGC mixed and SGC-enriched cul-
tures were cultured for 2–3 days, fixed in ice-cold methanol/
acetone (5min, 20C), washed with PBS and blocked with
NGS (10%) (1 h, room temperature). The cells were then incu-
bated with the primary antibodies (NeuN, 1:600, and glutam-
ine synthetase, 1:300) (1 h, room temperature), with
fluorescent secondary antibodies (1:600, polyclonal Alexa
Fluor

488, and polyclonal Alexa Fluor

594, Invitrogen)
(2 h, room temperature), mounted and digital images were
captured using an Olympus BX51.
Proximity ligation assay
Co-localization of TRPA1 and NOX2 in mouse trigeminal
ganglion was obtained using an in situ PLA detection kit
(Duolink, Olink Biosciences Inc.) as previously described
(Sullivan et al., 2015). In trigeminal ganglion sections (5 mm)
fluorescence images were obtained using Olympus BX51 and a
100 oil immersion objective. Negative control was per-
formed by omitting primary antibodies or proximity ligation
assay (PLA) probes.
Real-time PCR
RNA was extracted from trigeminal ganglion of C57BL/6 mice
after TRPA1 antisense or mismatch oligonucleotide (i.th.) and
of Adv-Cre; Trpa1fl/fl and Adv-Cre; Trpa1fl/fl. The standard
TRIzol

extraction method was used. Detailed methods are
reported in the Supplementary material.
Blood flow experiments
Cutaneous blood flow was assessed using a laser Doppler flow-
meter (Perimed Instruments) in anaesthetized in C57BL/6,
Trpa1+ / + and Trpa1/ mice. Cutaneous blood flow was
monitored by a probe (cutaneous type) fixed to the shaved
periorbital area, before and after the systemic administration
of GTN (10mg/kg, i.p.) or its vehicle. Before (0.5 h) GTN in-
jection, mice were treated with intraperitoneal HC-030031,
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disulfiram (both, 100mg/kg) and BIBN4096BS (1mg/kg) or
their vehicles and cutaneous blood flow was monitored for at
least 0.5 h. Baseline blood flow was calculated by the mean
flow value measured during a 5-min period before the stimulus.
The increase in cutaneous blood flow was calculated as the
percentage change over the baseline.
Statistical analysis
Statistical analysis was performed by the two-tailed Student’s t-
test for comparisons between two groups. A one-way ANOVA
followed by the post hoc Bonferroni’s test was used for com-
parisons of multiple groups. For behavioural experiments with
repeated measures, the two-way mixed model ANOVA fol-
lowed by the post hoc Bonferroni’s test was used. P50.05
was considered statistically significant (GraphPad Prism ver-
sion 5.00). The statistical tests and the exact F- and P-values
for each experiment are reported in Supplementary Table 2.
Data availability
The data that support the findings of this study are available
from the corresponding author on reasonable request.
Results
GTN evokes NO-mediated TRPA1-
independent vasodilatation and
TRPA1-dependent allodynia
Administration of GTN (1–10mg/kg, i.p.) to C57BL/6 mice
induced a dose-dependent and prolonged PMA (Fig. 1A).
GTN (10mg/kg, i.p.) also produced an early and transient
(0–10min) cutaneous increase in blood flow in the perior-
bital skin (Fig. 1B). GTN (1 and 10mg/kg, Fig. 1C and D,
respectively) evoked PMA in Trpa1+ / + mice, whereas
Trpa1/ mice were fully protected. However, the increase
in cutaneous blood flow evoked by GTN (10mg/kg) in
Trpa1+ / + mice was maintained in Trpa1/ mice (Fig.
1E). Genetic deletion of TRPV1 or TRPV4 channels did
not affect GTN-evoked PMA (Supplementary Fig. 1A
and B). Systemic GTN (10mg/kg) also induced sustained
mechanical allodynia in the hind paw of C57BL/6 and
Trpa1+ / + , but not Trpa1/ mice (Supplementary Fig. 1C
and D). This response, which indicates a general proalgesic
action of GTN, was not further investigated.
The TRPA1 antagonist, HC-030031, given (i.p.) 0.5 h
before and 1, 3, 4 and 5 h after GTN, transiently and com-
pletely reversed PMA at all time points (Fig. 1F and
Supplementary Fig. 1E). HC-030031 (1 h after GTN) re-
versed PMA induced by the lowest dose of GTN (1mg/
kg) (Supplementary Fig. 1F). Another channel antagonist,
A967079, given 0.5 h before and 1 h after GTN (10mg/kg)
also reversed allodynia (Supplementary Fig. 1G).
Antagonists of TRPV1 (capsazepine) and TRPV4 (HC-
067047), administered before GTN did not affect GTN-
induced PMA (Supplementary Fig. 1H and I).
Mitochondrial ALDH2 is known to generate NO from
GTN (Beretta et al., 2008). To determine the contribution
of NO to GTN-evoked PMA, mice were treated with the
ALDH2 inhibitor, disulfiram, or the specific NO scavenger,
cPTIO. Both disulfiram and cPTIO, when administered (i.p.)
0.5h before, but not 1h after, GTN, attenuated GTN-evoked
PMA (Fig. 1F). The ability of disulfiram and cPTIO to pre-
vent PMA if given before GTN indicates that NO is needed
to initiate GTN-evoked PMA. However, failure of disulfiram
and cPTIO to reverse established PMA suggests that add-
itional mechanisms are required to sustain PMA.
Pretreatment with disulfiram, but not with HC-030031
(both i.p., 0.5 h before GTN), attenuated the increase in peri-
orbital blood flow evoked by GTN (10mg/kg) (Fig. 1G).
NO, but not GTN, directly targets
TRPA1
To determine whether TRPA1 is directly gated by GTN
and/or NO, responses to different NO donors were inves-
tigated in vitro. GTN caused a concentration-dependent
increase in [Ca2+ ]i in trigeminal ganglion neurons from
C57BL/6 and Trpa1+ / + , but not from Trpa1/ mice
(Fig. 2A and B). The TRPA1 antagonist (HC-030031),
but not the TRPV1 or TRPV4 antagonists (capsazepine
or HC-067047, respectively), abolished responses (Fig.
2A). Key intracellular cysteine and lysine residues of
TRPA1 interact with oxidants and electrophilic agents
(Hinman et al., 2006). Whereas GTN increased [Ca2+ ]i
in hTRPA1-HEK293, HEK293 cells expressing a mutant
3C/K-Q/hTRPA1 were unresponsive (Fig. 2C). The NO
scavenger (cPTIO) or ALDH2 inhibitor (disulfiram) did
not affect GTN signals in neurons from C57BL/6 mice
(Fig. 2D). In contrast, the HC-030031-dependent Ca2+ -re-
sponse to a different NO donor, SNAP, was inhibited in
the presence of cPTIO (Fig. 2D). Thus, GTN activates
TRPA1 by targeting specific cysteine and lysine residues.
However, conversely to SNAP, the in vitro action of
GTN is not mediated through NO release.
Results obtained in vivo by local administration of NO
donors recapitulated the in vitro findings. Injection (s.c.) in
the periorbital area of the TRPA1 agonist, AITC, evoked
PMA that was reversed by local (s.c.) pretreatment with
HC-030031 (Supplementary Fig. 1J). Local (s.c.) NO
donors, GTN or SNAP, induced PMA in Trpa1+ / + , but
not Trpa1/ mice (Fig. 2E and F). Both local (s.c.) or
systemic (i.p.) TRPA1 antagonism by HC-030031 reversed
PMA evoked by local GTN or SNAP (Fig. 2G and H).
Systemic (i.p.) disulfiram or cPTIO did not affect PMA
evoked by local (s.c.) GTN (Fig. 2G). However, cPTIO
(i.p.) attenuated PMA evoked by local (s.c.) SNAP (Fig.
2H). Thus, GTN evokes allodynia by mechanisms that
depend from the route of administration. Local GTN
directly regulates TRPA1 gating, whereas systemic GTN
indirectly regulates TRPA1 by a process that involves
ALDH2-mediated liberation of NO.
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Oxidative stress and TRPA1 sustain
GTN-evoked mechanical allodynia
The NO scavenger (cPTIO) or ALDH2 inhibitor (disulfiram)
prevented GTN-evoked allodynia when administered before
GTN, but were ineffective when given after. Thus, NO is
necessary to initiate the hypersensitivity condition, but is not
sufficient for its maintenance. Since GTN stimulates oxida-
tive stress (Wenzl et al., 2009), we hypothesized that NO,
liberated from GTN, initiates the process that subsequently
sustains TRPA1-dependent PMA via reactive oxygen species
generation. Two different reactive oxygen species scavengers,
Figure 1 GTN induces PMA via a TRPA1-dependent mechanism. (A) Dose- and time-dependent PMA evoked by GTN in C57BL/6
mice. (B) Representative traces and pooled data of the increases in periorbital skin blood flow evoked by GTN (10mg/kg). PMA evoked by
(C) low (1mg/kg, i.p.) and (D) high (10mg/kg, i.p.) dose of GTN, in Trpa1+ / + and Trpa1/ mice. (E) Representative traces and pooled data of the
increases in periorbital skin blood flow evoked by GTN (10mg/kg) in Trpa1+ / + and Trpa1/ mice. (F) Pretreatment with systemic (i.p.) HC-
030031 (HC03; 100mg/kg), disulfiram (DSF, 100mg/kg) or cPTIO (0.6mg/kg) abates PMA measured 0.5 h after GTN (10mg/kg). HC03 but not
DSF and cPTIO (given after GTN) reduces PMA measured 2 h after GTN. (G) Representative traces and pooled data of the increases in
periorbital skin blood flow evoked by GTN (10mg/kg). DSF but not HC03, both given before GTN abolishes the increase in blood flow induced
by GTN. BL = baseline mechanical threshold; Veh = the vehicle of GTN. Dash (-) indicates combined vehicles of treatments. Arrows indicate
times of drug administration. AU = arbitrary units; PU = perfusion units. Error bars indicate mean  SEM, 6–8 mice per group. *P5 0.05,
**P5 0.01, ***P5 0.001 versus vehicle, Trpa1+ / + -vehicle and #P5 0.05, ##P5 0.01, ###P5 0.001 versus Trpa1+ / + -GTN or GTN; one-way or
two-way ANOVA with Bonferroni post hoc correction, and Student’s t-test.
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alpha lipoic acid and N-tert-butyl--phenylnitrone (PBN),
reversed PMA only when given (i.p.) 1 h after, but not
0.5h before GTN (Fig. 3A and B).
GTN-evoked PMA persisted for 8 h, but alpha lipoic
acid or PBN were unable to reverse PMA 5h post-GTN
(Fig. 3C), indicating that mediators other than reactive
oxygen species are required to sustain hypersensitivity
beyond 5 h. 4-HNE is a major electrophilic aldehyde that
is generated by free radical attack of polyunsaturated fatty
acids (Dalle-Donne et al., 2006), and is a TRPA1 agonist
(Trevisani et al., 2007). In contrast to reactive oxygen spe-
cies, which are short-lived, the biological activity of 4-HNE
may last for hours (Brame et al., 1999). NAC and L-carno-
sine efficiently scavenge ,b-unsaturated aldehydes, includ-
ing 4-HNE. NAC or L-carnosine (i.p.), administered before
GTN, did not attenuate the first phase of GTN-evoked
PMA (2 h), but strongly inhibited later phases (5 h) (Fig.
3B and C), indicating that carbonylic derivatives more
Figure 2 GTN-evoked PMA is mediated by NO. (A) Ca2+ -response to GTN in mouse trigeminal ganglion neurons, which also respond to
AITC or capsaicin (CPS), is attenuated by HC-030031 (HC03), but not by HC-067047 (HC06, TRPV4 antagonist) or capsazepine (CPZ, TRPV1
antagonist), and (B) abated by TRPA1 deletion. (C) Ca2+ -response to GTN or menthol in HEK293-cells expressing wild-type (wt) or mutant (3C/
K-Q) human TRPA1. (D) GTN-evoked Ca2+ -response in trigeminal ganglion neurons is unaffected by disulfiram (DSF) or cPTIO while SNAP-
evoked Ca2+ -response is abated by cPTIO and HC03. Veh = the vehicle of GTN. Dash (-) indicates combined vehicles of treatments. Error bars
indicate mean  SEM of n4 15 neurons or 50 cells (A–D). *P5 0.05, **P5 0.01, ***P5 0.001; one-way ANOVA with Bonferroni post hoc
correction. (E and G) Local (10 ml s.c.) GTN (10 mg) evokes a time-dependent PMA that is abated in Trpa1/ mice and by the pretreatment with
local (s.c.) and systemic (i.p.) HC03 (100 mg and 100mg/kg, respectively), but not with systemic DSF (100mg/kg, i.p.) and cPTIO (0.6mg/kg, i.p.). (F
and H) Local (10 ml s.c.) SNAP (40mg) induces a time-dependent PMA that is abated in Trpa1/ mice and prevented by pretreatment with local
(s.c.) and systemic (i.p.) HC03 (100 mg and 100mg/kg, respectively) and systemic cPTIO (0.6mg/kg, i.p.). BL = baseline mechanical threshold;
Veh = the vehicle of GTN. Dash (-) indicates combined vehicles of treatments. Arrows indicate time of drug administration. Error bars
indicate mean  SEM, 6–8 mice per group. **P5 0.01, ***P5 0.001 versus Trpa1+ / + -Veh, vehicle and #P5 0.05, ##P5 0.01, ###P5 0.001 versus
Trpa1+ / + -GTN, GTN, Trpa1 + / + -SNAP or SNA, one-way or two-way ANOVA with Bonferroni post hoc correction.
Trigeminal TRPA1/NOX and GTN-evoked pain BRAIN 2018: Page 7 of 17 | 7
Downloaded from https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awy177/5050181
by Azienda Ospedaliera Careggi user
on 10 July 2018
stable than reactive oxygen species sustain the final phase
of PMA.
GTN does not produce periorbital
allodynia by a local mechanism
Local injections of the TRPA1 agonist, AITC, and the NO
donors, GTN or SNAP, caused TRPA1-dependent PMA,
suggesting the involvement of TRPA1 on cutaneous nerve
terminals. However, PMA evoked by systemic GTN was
unaffected by local treatment with disulfiram, cPTIO, HC-
030031, alpha lipoic acid and NAC (Fig. 3D–F), excluding
that systemic GTN activates TRPA1 on cutaneous afferent
nerve fibres to induce PMA. Centrally administered TRPA1
antagonists, HC-030031 or A967079 (pre- or post-GTN,
i.th.), attenuated PMA-evoked by systemic GTN (Fig. 3G
and H and Supplementary Fig. 1K). Disulfiram or cPTIO
(pre-, but not post-GTN), alpha lipoic acid (post-, but not
pre-GTN) and NAC (pre- or post-GTN) (all i.th.) (Fig. 3G–I)
also attenuated PMA.
Figure 3 Prolonged PMA induced by GTN is mediated by oxidative stress. (A) PMA evoked by GTN (10mg/kg) in C57BL/6 mice is
not affected by the alpha lipoic acid (LA, 100mg/kg), NAC (250mg/kg), PBN (100mg/kg) or L-carnosine (Carn, 200mg/kg) (all pre-GTN). (B and
C) Alpha lipoic acid and PBN (all post-GTN) reduce PMA measured at 2 h not at 5 h. Pretreatment with NAC and Carn reach the maximum effect
in the reduction of PMA, 5 h after GTN. (D) PMA evoked by systemic (i.p.) GTN (10mg/kg) is unaffected by local (10ml, s.c.) cPTIO (60mg) or
disulfiram (DSF; 10 mg) (all pre-GTN), and by (E) HC-030031 (HC03; 50 mg) and alpha lipoic acid (LA, 5 mg) (all post-GTN). (F) Local (10 ml, s.c.)
administration of NAC (20mg, post-GTN) does not affect GTN-evoked PMA. (G) PMA evoked by systemic (i.p.) GTN (10mg/kg) is reversed by
intrathecal (5 ml, i.th.) HC03 (10mg), DSF (5 mg) and cPTIO (30mg) but not with alpha lipoic acid (10 mg) (all pre-GTN). (H) Intrathecal (i.th.) HC03
(10 mg) and alpha lipoic acid (10 mg), but not DSF (5 mg) and cPTIO (30 mg), (all post-GTN) reduce PMA measured 2 h after GTN. (I) Intrathecal
(i.th.) NAC (50 mg) (pre- or post-GTN) reduces GTN-evoked PMA. BL = baseline mechanical threshold; Veh = the vehicle of GTN. Dash (-)
indicates combined vehicles of treatments. Arrows indicate time of drug administration. Error bars indicate mean  SEM, 6–9 mice per group.
*P5 0.05, **P5 0.01, ***P5 0.001 versus vehicle, NAC-Veh. #P5 0.05, ##P5 0.01, ###P5 0.001 versus GTN, vehicle NAC-GTN; one-way or
two-way ANOVA with Bonferroni post hoc correction.
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GTN/NO targets TRPA1 in the soma
of trigeminal ganglion neurons to
generate oxidative stress
Failure of subcutaneous and ability of intrathecal drugs to
attenuate GTN-evoked PMA suggested the involvement of
central anatomical areas, including the terminals in the
dorsal horn of the brainstem and nociceptor cell bodies
in the trigeminal ganglion. To determine whether systemic
GTN induces oxidative stress in these locations, we mea-
sured two markers of oxidative and carbonylic stress,
H2O2 and 4-HNE, respectively. GTN, which failed to in-
crease H2O2 and 4-HNE in brainstem, caused a rapid and
transient increase in H2O2 (1–3 h) and a gradual and sus-
tained increase in 4-HNE (4–6 h) in the trigeminal ganglion
neurons (Fig. 4A and B). cPTIO and disulfiram (both pre-
GTN) and alpha lipoic acid (post-GTN) blunted the H2O2
increase (at 2 h) (Fig. 4C). cPTIO and NAC (pre-GTN), and
alpha lipoic acid (post-GTN) blunted the 4-HNE signal (at
4 h) (Fig. 4D). Unexpectedly, antagonism (HC-030031) or
genetic deletion of TRPA1 also attenuated GTN-induced
increases in H2O2 or 4-HNE (Fig. 4 C–E). These data sug-
gest that oxidative stress generation, which seems to medi-
ate GTN-evoked PMA, is initiated by NO-induced
activation of TRPA1 within the trigeminal ganglion.
Sensory neurons and SGCs are present in the trigeminal
ganglion (Fig. 5A). To determine which cell type generates
GTN/NO-evoked oxidative stress, C57BL/6 mice were trea-
ted with resiniferatoxin, which is known to defunctionalize
TRPV1-expressing neurons (Pecze et al., 2009), which co-
express TRPA1 (Karai et al., 2004; De Logu et al., 2017).
Treatment with resiniferatoxin, which suppressed eye
wiping evoked by TRPV1 and TRPA1 agonists (capsaicin
and AITC, respectively) (Supplementary Fig. 1L), attenu-
ated both GTN-evoked PMA and H2O2 generation (Fig.
5B), supporting a role of TRPV1/TRPA1-positive neurons
in these responses. GTN stimulated release of H2O2 from
mixed cultures of trigeminal ganglion neurons/SGCs (Fig.
5C), but not from primary cultures of isolated SGCs (Fig.
5D). Removal of extracellular Ca2+ or pre-exposure to a
high capsaicin concentration that, similar to resiniferatoxin,
desensitizes TRPV1/TRPA1-positive neurons (Nassini et al.,
2015), attenuated GTN-evoked increase in H2O2 in mixed
cultures of trigeminal ganglion neurons/SGCs (Fig. 5C).
GTN, AITC and SNAP increased H2O2 release from tri-
geminal ganglion neurons/SGCs mixed cultures in a HC-
030031-dependent manner (Fig. 5C).
Intrathecal administration of TRPA1 antisense oligo-
nucleotide downregulated Trpa1 mRNA expression in
trigeminal ganglion neurons (Fig. 5E) and reduced AITC-
evoked eye wiping (Supplementary Fig. 1M). TRPA1 anti-
sense oligonucleotide attenuated GTN-evoked PMA and
H2O2 increase in trigeminal ganglion neurons (Fig. 5E).
Further evidence for the role of neuronal TRPA1 in
GTN-evoked oxidative stress and allodynia was obtained
by studying Advillin-Cre + ; Trpa1fl/fl mice, which exhibited
reduced TRPA1 mRNA in trigeminal ganglion neurons
(Fig. 5F) and TRPA1-mediated eye wiping evoked by
AITC (Supplementary Fig. 1M). GTN failed to evoke
PMA or H2O2 generation in trigeminal ganglion neurons
in Advillin-Cre + ; Trpa1fl/fl mice (Fig. 5F), thus supporting
that GTN/NO initiates a TRPA1-dependent and oxidative
stress-mediated mechanism that perpetuates nociceptor ac-
tivation by an autocrine pathway that is confined to the
trigeminal ganglion.
TRPA1 and NOXs in the soma of
trigeminal ganglion nociceptors
maintain GTN-evoked allodynia
To explore the mechanism by which oxidative stress sustains
GTN-evoked allodynia within trigeminal ganglion neurons
we localized immunoreactivity for NOX1, NOX2, and
NOX4 in mouse trigeminal ganglion neurons but not in
SGCs (Supplementary Fig. 2A), confirming previous studies
(Bedard and Krause, 2007). Immunoreactivities for the three
NOX isoforms colocalized with that for TRPA1 (Fig. 6A).
The non-selective NOX inhibitor, apocynin (i.p., post- but
not pre-GTN) reversed GTN-evoked allodynia (Fig. 6B and
C). Selective NOX2 (gp91ds-tat) or NOX1 (ML171) inhibi-
tors (i.p., post- but not pre-GTN) attenuated, and their com-
bination abolished, GTN-evoked PMA (Fig. 6B and C). The
NOX4 inhibitor GKT137831 reduced, and the combination
of GKT137831 and gp91ds-tat abolished, GTN-evoked allo-
dynia (Supplementary Fig. 2B and C). However, since
GKT137831 also inhibits NOX1, the role of NOX4 remains
uncertain. Furthermore, a proximity ligation assay showed
that NOX2 and TRPA1 are closely located in trigeminal
ganglion neuronal cell bodies (Fig. 6D), suggesting that
their interaction could underlie efficient reactive oxygen spe-
cies release. Thus, the soma of TRPA1-expressing trigeminal
ganglion neurons possesses the biochemical machinery
required to initiate and sustain oxidative stress evoked by
GTN.
CGRP contributes only in part to
GTN-evoked allodynia
As CGRP is a key mediator of migraine headaches (Ho et al.,
2010; Edvinsson, 2015) the contribution of CGRP to GTN-
induced vasodilation and PMA was explored. Two different
CGRP receptor antagonists, CGRP8-37 and BIBN4096BS
(olcegepant) given (i.p.) after, but not before GTN, partially
inhibited PMA (Fig. 7A). CGRP8-37 or BIBN4096BS admin-
istered centrally (i.th.) either before or after GTN did not
affect GTN-evoked PMA (Fig. 7B). Local CGRP (0.5–5mg/
10ml s.c.) in the periorbital area induced a dose-dependent
and sustained (4h) PMA (Fig. 7C). Local (s.c.) pretreatment
with CGRP8-37 or BIBN4096BS prevented CGRP-induced
PMA (Fig. 7D). Local administration of CGRP8-37 or
BIBN4096BS after, but not before GTN, partially attenuated
PMA in a manner similar to that produced by their systemic
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administration (Fig. 7E). GTN-evoked increase in cutaneous
blood flow was unaffected by the pretreatment with
BIBN4096BS (Fig. 7F). Thus, the early vasodilation evoked
by GTN is unrelated to CGRP.
Discussion
We report that the delayed and prolonged GTN-evoked
PMA in mice is entirely TRPA1-dependent. Two chemically
unrelated TRPA1 antagonists, but not TRPV1 or TRPV4
antagonists, completely reversed PMA. Furthermore, dele-
tion of Trpa1, but not Trpv1 or Trpv4, prevented the de-
velopment of PMA. A recent report that TRPA1
antagonism attenuates GTN potentiation of formalin-
evoked periorbital allodynia in rats is in line with our find-
ings (Demartini et al., 2017). We exposed mice to a dose of
GTN (10mg/kg) that has been used by others (Tassorelli
et al., 2003; Bates et al., 2010; Farkas et al., 2016), but
which exceeds the dose used in humans (40 mg/kg, i.v.)
(Iversen and Olesen, 1996; Olesen, 2008). However, gen-
etic deletion or pharmacological blockade of TRPA1 also
suppressed PMA evoked by a low dose of GTN (1mg/kg).
The observation that, after correction for the mouse to man
conversion factor (Reagan-Shaw et al., 2008), this dose is
only 2-fold higher than the human dose, supports the trans-
lational relevance of the role of TRPA1 in GTN-evoked
allodynia in mice.
NO activation of TRPA1, either directly, or indirectly via
its by-products, through nitrosylation of cysteinyl residues,
is an important posttranslational mechanism of channel
regulation (Miyamoto et al., 2009). NO donors activate
TRPA1 in cultured trigeminal ganglion neurons and
hTRPA1-HEK293 cells by distinct mechanisms. As Ca2+
responses by SNAP, but not those by GTN, were inhibited
by the NO scavenger, cPTIO, NO does not seem required
for TRPA1 activation by GTN. It is possible that under
in vitro conditions NO is released with insufficient velocity
or in insufficient amounts to elicit TRPA1 gating, while the
channel is engaged directly by GTN which binds to the
same key cysteine/lysine residues required for channel acti-
vation by electrophilic and oxidant molecules (Hinman
et al., 2006; Kozai et al., 2014).
In vivo GTN induces PMA via diverse anatomical path-
ways, mechanisms and time courses that depend from the
route of administration. As the ALDH2 inhibitor, disul-
firam, and the NO scavenger, cPTIO, blocked PMA elicited
by systemic, but not local administration of GTN, local
GTN likely causes allodynia by targeting TRPA1 by a
direct NO-independent mechanism, whereas systemic
GTN by an indirect, NO dependent pathway. As a conse-
quence, the ability of NO released from GTN to target
TRPA1 requires that the conversion occurs distant
(Beretta et al., 2008) from the site where NO engages
the channel. Evidence that NO must have spent some
time in the extracellular environment before leading to
Figure 4 GTN generates oxidative stress in trigeminal ganglion via NO and TRPA1. (A and B) Systemic (i.p.) GTN increases H2O2
levels and 4-HNE staining in trigeminal ganglion, but not in brain stem of C57BL/6 mice. (C) Two hours after GTN the increase in H2O2 in
trigeminal ganglion neurons, is abolished by systemic (i.p.) cPTIO (0.6mg/kg) and disulfiram (DSF, 100mg/kg) (all pre-GTN) or alpha lipoic acid
(LA) or HC-030031 (HC03, both 100mg/kg) (all post-GTN). (D) Representative images and pooled data of 4-HNE staining in trigeminal ganglion
neurons, 4 h after GTN (10mg/kg) administration in C57BL/6 mice treated systemically (i.p.) with cPTIO (0.6mg/kg) or NAC (250mg/kg) (all pre-
GTN), or with HC03 and alpha lipoic acid (both, 100mg/kg) (all post-GTN). (E) Systemic (i.p.) GTN (10mg/kg) increases H2O2 levels and 4-HNE
staining in trigeminal ganglion neurons from Trpa1+ / + , but not Trpa1/ mice. BL = baseline level of H2O2 or 4-HNE; Veh = the vehicle of GTN.
Dash (-) indicates combined vehicles of treatments. Error bars indicate mean  SEM, 4–6 mice per group. *P5 0.05, **P5 0.01, ***P5 0.001;
###P5 0.001; one-way ANOVA with Bonferroni post hoc correction and Student’s t-test.
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S-nitrosothiol formation (Zhang and Hogg, 2004) supports
this explanation. Furthermore, the observation that cPTIO
and disulfiram prevent allodynia when administered before,
but not after systemic GTN implies that NO is initially
necessary, but is not subsequently sufficient, to sustain the
allodynia. Attenuation by two different TRPA1 antagonists,
HC-030031 or A967079, of GTN-evoked allodynia was a
transient phenomenon, probably because of the limited
half-lives of the antagonists in mice. These findings suggest
that to maintain allodynia, TRPA1 must be engaged
continuously by one or more mediators generated by
GTN/NO and whose identity and source are unknown.
GTN generates oxidative stress (Wenzl et al., 2009). The
observation that pretreatment with the reactive oxygen spe-
cies scavengers, alpha lipoic acid or PBN, did not prevent
GTN-evoked PMA, but attenuated allodynia from for 3–
4 h after GTN, indicates that reactive oxygen species do not
initiate the response, but mediate the ensuing phase.
However, additional TRPA1 agonists must contribute to
the final phase of PMA, when antioxidants were ineffective.
Figure 5 GTN targets neuronal TRPA1 to generate periorbital oxidative stress and PMA. (A) Neurons (identified by neuronal
nuclei, NeuN), SGCs (identified by glutamine synthetase, GS) and TRPA1 staining in trigeminal ganglion. (B) Neuronal defunctionalization with
resiniferatoxin prevents systemic (i.p.) GTN-evoked PMA and H2O2 increase in trigeminal ganglion neurons of C57BL/6 mice. (C) H2O2 release
elicited by GTN from trigeminal ganglion neurons-SGCs mixed cultures (see staining for NeuN/GS) is inhibited by extracellular Ca2+ removal
(Ca2+ -free), pre-exposure to capsaicin (CPS-des) or HC-030031 (HC03), which also inhibits H2O2 release elicited by AITC or SNAP. (D) In SGC-
enriched cultures (see staining for GS, but not NeuN) GTN does not release H2O2. (E) Intrathecal TRPA1 antisense oligonucleotide inhibits
TRPA1 mRNA expression, systemic (i.p.) GTN-evoked PMA and H2O2 increase in trigeminal ganglion neurons. (F) TRPA1 mRNA expression in
trigeminal ganglion neurons from control and Advillin-Cre; Trpa1fl/fl (Adv-Cre; Trpa1fl/fl). Systemic (i.p.) GTN-evoked PMA and H2O2 increase in
trigeminal ganglion neurons are reduced in Adv-Cre; Trpa1fl/fl mice. BL = baseline mechanical threshold; Veh = the vehicle of GTN. Dash (-)
indicates vehicles of treatments. Error bars indicate mean  SEM, 6–8 mice per group or 2–7 replicates from three independent experiments.
*P5 0.05, **P5 0.01, ***P5 0.001 versus resiniferatoxin-vehicle (RTX-Veh), mismatch oligonucleotide-vehicle (MM-Veh) and control-Veh;
##P5 0.01, ###P5 0.001 versus vehicle resiniferatoxin-GTN, MM-GTN, control-GTN, GTN, AITC or SNAP, one-way or two-way ANOVA with
Bonferroni post hoc correction and Student’s t-test.
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Carbonylic by-products of oxidative stress, including
4-HNE, have half-lives longer than reactive oxygen species
(Brame et al., 1999), and are known to target TRPA1
(Trevisani et al., 2007). PMA attenuation by NAC and L-
carnosine, which efficiently quenches aldehydes, indicates
that 4-HNE and/or related aldehydes engage TRPA1 to
mediate the terminal phase of PMA, from 3–4 to 8 h
after GTN.
Failure of local and efficacy of intrathecal antioxidants
and TRPA1 antagonists to block PMA indicate that sys-
temic GTN/NO does not target TRPA1 on cutaneous ter-
minals of nociceptor and suggests the involvement of
TRPA1 in a central site, such as the soma and central ter-
minals in the brainstem of trigeminal ganglion neurons.
Assessment of GTN-induced oxidative stress showed no
change in the dorsal brain stem, whereas a marked increase
in H2O2 and 4-HNE levels were found in trigeminal
ganglion neurons. Remarkably, the time course of H2O2
formation (1–3 h) paralleled the ability of reactive oxygen
species scavengers to attenuate PMA, and the time course
of increased 4-HNE staining (3–6 h) paralleled the ability of
aldehyde scavengers to inhibit PMA.
Primary sensory neurons and associated SGCs are most
abundant cell types in trigeminal ganglion. The observa-
tion that resiniferatoxin, which defunctionalizes TRPV1/
TRPA1 expressing nociceptors (Pecze et al., 2009), attenu-
ated GTN-evoked H2O2 generation in vivo, suggests that
trigeminal ganglion neurons rather than SGCs generate
oxidative stress. As pharmacological blockade of TRPA1,
global TRPA1 deletion, selective deletion of TRPA1 in per-
ipheral sensory neurons and TRPA1 knockdown all abro-
gated GTN-evoked oxidative stress and PMA, TRPA1
expressed by trigeminal ganglion sensory neurons seems
to be a critical step for PMA. Although various TRP
Figure 6 GTN evokes PMA via NADPH oxidase dependent mechanism. (A) Representative images of TRPA1, NOX1, NOX2 and
NOX4 staining in mouse trigeminal ganglion. (B) The unselective NOX inhibitor, apocynin (APO; 100mg/kg), the selective (C) NOX2 (gp91ds-tat
peptide, gp91; 10mg/kg) or the selective NOX1 (ML171; 60mg/kg) (i.p., all pre-GTN) do not affect PMA evoked by systemic (i.p.) GTN (10mg/
kg). (C) APO (100mg/kg), gp91 (10mg/kg) or ML171 (60mg/kg) (i.p., all post-GTN) partially reduce PMA. The combination of gp91 and ML171
(i.p., post-GTN) reverses PMA measured 2 h after GTN. (D) In situ proximity ligation assays (PLAs) for TRPA1: NOX2 in mouse trigeminal
ganglion labelled with NeuN. Veh = the vehicle of GTN. Dash (-) indicates vehicles of treatments. Error bars indicate mean  SEM, 7–8 mice per
group. ***P5 0.001 versus vehicle. ###P5 0.001 versus GTN; one-way ANOVA with Bonferroni post hoc correction.
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channels can promote reactive oxygen species release
(Shimizu et al., 2014), to our knowledge this is the first
evidence that TRPA1 expressed by cell bodies of primary
sensory neurons increase the tissue burden of oxidative
stress. Sensory neurons express several NOX isoforms
that may mediate the GTN/NO/TRPA1 signal (Bedard
and Krause, 2007). Trigeminal ganglion neurons, but not
SGCs, co-express TRPA1 and NOX1, NOX2 and NOX4,
and the NOX inhibitor apocynin reverses GTN-evoked
mechanical allodynia, thus suggesting that NOXs
Figure 7 CGRP released from periorbital nerve terminals contributes to GTN evoked PMA. (A) PMA evoked by systemic (i.p.)
GTN (10mg/kg) is partially reduced by i.p. administration of CGRP8-37 (4 mmol/kg) or BIBN4096BS (BIBN; 1mg/kg), when given post-, but not
pre-GTN. (B) Intrathecal (i.th.) administration of CGRP8-37 (5 nmol) or BIBN (1 mg) pre- and post-GTN (10mg/kg) does not affect GTN-evoked
PMA. (C) Local (s.c.) CGRP (0.5-5 mg) evokes a dose- and time-dependent PMA. (D) Pretreatment with local (s.c.) BIBN (4 nmol) or CGRP8-37
(10 nmol) prevents CGRP (5 mg)-evoked PMA. (E) Local (s.c.) CGRP8-37 (10 nmol) or BIBN (4 nmol) reduce PMA when given post-, but not pre-
GTN (i.p., 10mg/kg). BL = baseline mechanical threshold; Veh = the vehicle of GTN or CGRP. Dash (-) indicates vehicles of treatments. Data are
presented as mean  SEM of 6–8 mice per group. ***P5 0.001 versus Veh. #P5 0.05, ###P5 0.001 versus GTN or CGRP; one-way and two-way
ANOVA with Bonferroni post hoc correction. (F) Representative traces and pooled data of the increases in periorbital skin blood flow evoked by
GTN (i.p., 10 mg/kg). Pretreatment with systemic (i.p.) BIBN (1mg/kg) does not affect the early increase in blood flow. Veh = the vehicle of GTN.
Data are presented as mean  SEM of 6–7 mice per group. **P5 0.01 versus vehicle; one-way ANOVA with Bonferroni post hoc correction.
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expressed by trigeminal ganglion neurons and located
downstream from TRPA1 generate the pro-allodynic oxi-
dative burden. NOX1 and NOX2 isoforms provide a
major contribution, since the combination of selective
NOX1 and NOX2 inhibitors afforded complete inhibition
of allodynia. Notably, similar to alpha lipoic acid, the cap-
acity of NOX inhibitors to suppress allodynia faded with
time and was absent when the drugs were administered 3–
4 h after GTN.
Several findings of the current study support the hypoth-
esis that TRPA1/NOXs, reactive oxygen species and alde-
hydes sustain GTN-evoked PMA by an action that is
confined to trigeminal ganglion neurons. First, GTN
induced reactive oxygen species/4-HNE in trigeminal gan-
glion but not the brainstem. In particular, failure to identify
any increase in HNE staining in any specific brainstem area
supports the hypothesis that oxidative stress is not gener-
ated at this level. Second, intrathecal administration of
TRPA1 channel antagonists or antisense oligonucleotides
attenuated this response. Third, both GTN-evoked PMA
and reactive oxygen species/4-HNE generation were attenu-
ated by resiniferatoxin, which selectively desensitizes
TRPV1-expressing primary sensory neurons, a population
that encompasses the TRPA1-positive subpopulation (Karai
et al., 2004; De Logu et al., 2017). Finally, similar attenu-
ation was found in mice expressing Cre-recombinase from
the locus of the primary sensory neuron-specific gene
Advillin (Hasegawa et al., 2007; Zurborg et al., 2011;
Guan et al., 2016), resulting in a selective Trpa1 mRNA
attenuation in nociceptors. Although our findings suggest a
key role for TRPA1 in trigeminal ganglion neurons, the
present study did not systematically investigate the possibil-
ity that TRPA1 activation and oxidative stress in the CNS
also contribute to GTN-evoked PMA. The ability of cen-
trally administered NO donors to affect the function of
neurons of the spinal trigeminal nucleus (Koulchitsky
et al., 2004, 2009) suggests that GTN can also act cen-
trally. Furthermore, the cell bodies of trigeminal ganglion
neurons that mediate allodynia via TRPA1/NOX/oxidative
stress may belong to meningeal nociceptors, which are
known to contribute to the sensitisation process observed
after exposure to inflammatory mediators or GTN
(Strassman et al., 1996; Levy et al., 2004; Zhang et al.,
2013).
The beneficial action of CGRP/CGRP receptor blockade
by small molecules or monoclonal antibodies indicate that
CGRP is a major mediator of migraine headaches
(Ho et al., 2010; Edvinsson, 2015). The observation that
two different CGRP receptor antagonists, when adminis-
tered by systemic or local routes, but not central adminis-
tration, reduced GTN-evoked PMA suggests that CGRP
acts at a peripheral site. One possible explanation is that
excitation of the NO/TRPA1/NOX pathway in the soma of
trigeminal ganglion neurons generates antidromic action po-
tentials, which ultimately invade cutaneous nerve terminals
to promote local CGRP release. The observation that a
CGRP monoclonal antibody, which does not cross the
blood–brain barrier and should act peripherally, attenuates
PMA-induced by sodium nitroprusside plus sumatriptan in
rats (Kopruszinski et al., 2017), supports the existence of a
peripheral mechanism. However, further studies are
required to examine the effects of GTN on antidromic
transmission in trigeminal ganglion neurons. Our findings
that CGRP provides a limited and delayed contribution to
the allodynia may explain the failure of BIBN4096BS to
reduce GNT-evoked migraine-like pain in patients
(Tvedskov et al., 2010). Notably, we report that the early
periorbital vasodilation elicited by GTN is entirely due to
ALDH2-dependent NO formation, but neither TRPA1 nor
CGRP are involved. Thus, vasodilatation and allodynia are
temporally and mechanistically distinct. While vasodilata-
tion is probably due to a direct NO action in the vascular
smooth muscle, allodynia is a neuronal phenomenon
mediated by TRPA1 activation and the ensuing oxidative
stress.
Our present results suggest that systemic GTN is con-
verted by ALDH2 to NO that causes a transient vasodila-
tation unrelated to TRPA1 and most probably due to a
direct action of the gaseous mediator on smooth muscle
guanylyl cyclase (Fig. 8). NO and/or its by-products also
target TRPA1/NOXs in the soma of trigeminal ganglion
neurons to increase reactive oxygen species/reactive car-
bonylic species, thereby sustaining mechanical allodynia.
In this view, the channel that triggers the oxidative burst
is expressed by the same sensory neurons that potentially
mediate the allodynia. Thus, it is not possible to discrimin-
ate whether TRPA1, in addition to generating the proalge-
sic oxidative stress, is also the final mediator of the
hypersensitivity. Nevertheless, since TRPA1 is a major
sensor of oxidative and carbonylic stress (Trevisani et al.,
2007; Andersson et al., 2008; Materazzi et al., 2008), it is
possible that reactive oxygen species/4-HNE, generated by
TRPA1 activated by GTN/NO, target the same neuronal
channel to signal allodynia. TRPA1 antagonists, which
are currently in clinical development, or established anti-
migraine drugs, which have recently been identified as se-
lective channel inhibitors (Bigal et al., 2002; Nassini et al.,
2015), may be used to test whether a mechanism similar to
the present one mediates the delayed attack evoked by
GTN in migraineurs.
A limitation of our study is that GTN-evoked PMA in
naı¨ve mice may not fully replicate migraine in patients.
However, periorbital allodynia has been successfully used in
rodents to identify neural pathways that are relevant for mi-
graine pathophysiology, such as those responsible for head-
ache triggered by overuse of medications (De Felice et al.,
2010; Kopruszinski et al., 2017). In addition, GTN provoca-
tion studies report that healthy volunteers experience both an
early headache during GTN infusion (Iversen et al., 1989),
and also a delayed headache, although usually milder than in
migraineurs (Sicuteri et al., 1987; Olesen et al., 1993; Perrotta
et al., 2011). Moreover, cutaneous allodynia, which is usually
localized to the temporal and periocular areas (Drummond,
1987) occurs in 80% of migraine attacks and can be
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detected also in extracephalic areas (Burstein et al., 2000).
The report that GTN evokes a series of typical premonitory
symptoms (Afridi et al., 2004), in addition to headaches,
strengthens the value of studying allodynia as part of the
various symptoms of the migraine attack. Such sensitization,
deriving from activation of meningeal nociceptors by locally-
released inflammatory mediators (Strassman et al., 1996),
may lead to sensitization of central trigeminal neurons that
receive convergent input from the dura and skin (Burstein
et al., 1998). Endogenous mediators and exogenous chem-
icals, including GTN, elicit delayed sensitization that, via dy-
namic changes in meningeal arteries (Zhang et al., 2013) and
central second order trigeminovascular neurons (Burstein
et al., 1998), may be observed in periorbital skin and other
cutaneous areas. Our data suggest that the TRPA1/NOX
pathway in the soma of trigeminal neurons, in addition to
the previously reported peripheral or central sites, contributes
to GTN-evoked allodynia.
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